VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
VERAXA Biotech AG and Voyager Acquisition Corp. (NASDAQ:VACH) have announced the filing of a Form F-4 Registration Statement with the SEC for their proposed business combination. The transaction values VERAXA's equity contribution at $1.3 billion, with VERAXA shareholders receiving approximately 130 million ordinary shares in the combined company.
The combined entity is expected to have a pro forma equity value of $1.64 billion at closing, with potential access to $253 million in cash held in trust by Voyager. VERAXA's existing shareholders will roll over 100% of their equity into the combined company. The merger, unanimously approved by both boards, is expected to close in Q4 2025, subject to shareholder approval and customary closing conditions.
VERAXA Biotech AG e Voyager Acquisition Corp. (NASDAQ:VACH) hanno annunciato il deposito di una dichiarazione di registrazione Modulo F-4 presso la SEC per la loro proposta fusione aziendale. L'operazione valuta il contributo azionario di VERAXA a 1,3 miliardi di dollari, con gli azionisti di VERAXA che riceveranno circa 130 milioni di azioni ordinarie nella società risultante dalla fusione.
La società combinata dovrebbe avere un valore azionario pro forma di 1,64 miliardi di dollari al momento della chiusura, con un potenziale accesso a 253 milioni di dollari in contanti trattenuti in trust da Voyager. Gli azionisti attuali di VERAXA convertiranno il 100% delle loro azioni nella nuova società. La fusione, approvata all'unanimità da entrambi i consigli di amministrazione, è prevista per la chiusura nel quarto trimestre del 2025, subordinata all'approvazione degli azionisti e alle condizioni consuete di chiusura.
VERAXA Biotech AG y Voyager Acquisition Corp. (NASDAQ:VACH) han anunciado la presentación de una Declaración de Registro Formulario F-4 ante la SEC para su propuesta combinación de negocios. La transacción valora la contribución de capital de VERAXA en 1.3 mil millones de dólares, con los accionistas de VERAXA recibiendo aproximadamente 130 millones de acciones ordinarias en la empresa combinada.
Se espera que la entidad combinada tenga un valor patrimonial pro forma de 1.64 mil millones de dólares al cierre, con acceso potencial a 253 millones de dólares en efectivo mantenidos en fideicomiso por Voyager. Los accionistas actuales de VERAXA transferirán el 100% de su capital a la compañía combinada. La fusión, aprobada por unanimidad por ambas juntas directivas, se espera que se cierre en el cuarto trimestre de 2025, sujeto a la aprobación de los accionistas y condiciones habituales de cierre.
VERAXA Biotech AG와 Voyager Acquisition Corp. (NASDAQ:VACH)는 제안된 사업 결합을 위해 SEC에 Form F-4 등록 명세서를 제출했다고 발표했습니다. 이번 거래는 VERAXA의 지분 가치를 13억 달러로 평가하며, VERAXA 주주들은 합병 회사에서 약 1억 3천만 보통주를 받게 됩니다.
합병된 법인은 마감 시점에 16억 4천만 달러의 프로포르마 지분 가치를 가질 것으로 예상되며, Voyager가 신탁으로 보유한 2억 5천 3백만 달러의 현금에 접근할 수 있습니다. VERAXA 기존 주주들은 보유 지분 100%를 합병 회사로 이전할 예정입니다. 양사 이사회가 만장일치로 승인한 이번 합병은 주주 승인과 일반적인 마감 조건을 조건으로 2025년 4분기에 완료될 예정입니다.
VERAXA Biotech AG et Voyager Acquisition Corp. (NASDAQ:VACH) ont annoncé le dépôt d'une déclaration d'enregistrement Formulaire F-4 auprès de la SEC pour leur projet de fusion d'entreprise. La transaction valorise la contribution en actions de VERAXA à 1,3 milliard de dollars, les actionnaires de VERAXA recevant environ 130 millions d'actions ordinaires dans la société combinée.
L'entité combinée devrait avoir une valeur des capitaux propres pro forma de 1,64 milliard de dollars à la clôture, avec un accès potentiel à 253 millions de dollars en liquidités détenues en fiducie par Voyager. Les actionnaires actuels de VERAXA réinvestiront 100 % de leur capital dans la société combinée. La fusion, approuvée à l'unanimité par les deux conseils d'administration, devrait être finalisée au 4e trimestre 2025, sous réserve de l'approbation des actionnaires et des conditions habituelles de clôture.
VERAXA Biotech AG und Voyager Acquisition Corp. (NASDAQ:VACH) haben die Einreichung einer Form F-4-Registrierungserklärung bei der SEC für ihre vorgeschlagene Geschäftsverbindung bekanntgegeben. Die Transaktion bewertet den Eigenkapitalbeitrag von VERAXA mit 1,3 Milliarden US-Dollar, wobei die VERAXA-Aktionäre etwa 130 Millionen Stammaktien des kombinierten Unternehmens erhalten.
Das kombinierte Unternehmen wird voraussichtlich einen pro forma Eigenkapitalwert von 1,64 Milliarden US-Dollar zum Zeitpunkt des Abschlusses haben und potenziellen Zugriff auf 253 Millionen US-Dollar in bar, die von Voyager treuhänderisch gehalten werden. Die bestehenden Aktionäre von VERAXA werden 100 % ihres Eigenkapitals in das kombinierte Unternehmen einbringen. Die Fusion, die von beiden Vorständen einstimmig genehmigt wurde, soll im 4. Quartal 2025 abgeschlossen werden, vorbehaltlich der Zustimmung der Aktionäre und der üblichen Abschlussbedingungen.
- None.
- Transaction subject to shareholder approval and closing conditions
- SPAC cash proceeds dependent on potential redemptions by public shareholders
- Registration Statement not yet declared effective by SEC
Insights
VERAXA's $1.64B SPAC merger progresses with F-4 filing, signaling path to public markets with potential $253M cash infusion.
The F-4 registration statement filing marks a crucial milestone in VERAXA Biotech's journey to becoming a publicly traded company through its merger with Voyager Acquisition Corp. This $1.64 billion SPAC transaction provides a clear valuation benchmark for this emerging cancer therapy developer.
The deal structure reveals important insights: VERAXA's $1.3 billion equity contribution shows strong confidence in their business model, while existing shareholders rolling over 100% of their equity demonstrates commitment to long-term value creation rather than immediate liquidity. This structure aligns management incentives with future performance.
Perhaps most significant is the potential $253 million cash infusion (assuming no redemptions), which would substantially strengthen VERAXA's balance sheet. For a biotech company developing novel cancer therapies, this capital could accelerate R&D programs, expand clinical trials, and extend operational runway - critical for navigating the capital-intensive drug development process.
The projected Q4 2025 closing timeline appears realistic, though it's contingent on shareholder approvals and regulatory clearances. With both boards unanimously approving the transaction, internal alignment exists, but external shareholder support remains the key variable, particularly given the recent trend of high redemption rates in SPAC transactions.
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in regards to the proposed Business Combination Agreement announced April 23, 2025.
“We are excited to share this pivotal milestone in VERAXA's journey toward becoming a public company,” commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “The filing of our Registration Statement marks a significant step forward in our path to accessing the public capital markets and vision of bringing the next generation of safe and highly effective cancer therapies to patients. We remain focused on executing the merger effectively with Voyager as we move forward together.”
While the Registration Statement has not been declared effective, and the information included within is not complete and subject to change, it contains key information about Voyager's business and securities listing, VERAXA’s drug development pipeline, technology platform, licensing partnerships, intellectual property, and research and development program. It also includes the proposed Business Combination Agreement and the proposals to be considered by SPAC’s shareholders.
Transaction Overview
Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution to the Business Combination will amount to approximately
Assuming a share price of
Upon the closing of the Business Combination, VERAXA anticipates access to approximately up to
The boards of directors of both Voyager and VERAXA unanimously approved the Business Combination. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions.
Additional information about the transaction will be provided in a Current Report on Form 8-K that will contain an investor presentation to be filed with the SEC and will be available at www.sec.gov. In addition, VERAXA will file other documents regarding the Business Combination with the SEC. This communication is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Voyager has filed or may file with the SEC in connection with the Business Combination.
Advisors
Anne Martina Group is acting as sole M&A advisor to VERAXA. Duane Morris LLP is acting as legal counsel to VERAXA. Winston & Strawn LLP is serving as legal counsel to Voyager. Cantor Fitzgerald is acting as Voyager's capital markets advisor.
About VERAXA Biotech
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For more information, please visit www.veraxa.com.
On April 22, 2025, VERAXA entered into a definitive business combination agreement (the "Business Combination Agreement") with Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, "Voyager"). Upon closing of the Business Combination Agreement, VERAXA is expected to become a publicly traded company listed on NASDAQ.
About Voyager Acquisition Corp.
Voyager is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Our team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, we not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry. For more information, please visit https://www.voyageracq.com.
Participants In the Solicitation
Voyager, VERAXA, and their respective directors, executive officers, other members of management, and employees may be deemed participants in the solicitation of proxies from Voyager’s stockholders with respect to the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of Voyager’s directors and officers in Voyager’s filings with the SEC, including, when filed with the SEC, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information with respect to VERAXA’s directors and executive officers will also be included in the proxy statement/prospectus. You may obtain free copies of these documents as described below under the heading "Additional Information and Where to Find It".
Non-Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Voyager or VERAXA, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release includes certain statements that may be considered forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, without limitation, statements about future events or Voyager’s or VERAXA’s future financial or operating performance. For example, statements regarding VERAXA’s anticipated growth and the anticipated growth and other metrics, statements regarding the benefits of the Business Combination, and the anticipated timing of the completion of the Business Combination are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology.
These forward-looking statements regarding future events and the future results of Voyager and VERAXA are based on current expectations, estimates, forecasts, and projections about the industry in which VERAXA operates, as well as the beliefs and assumptions of Voyager’s management and VERAXA’s management. These forward-looking statements are only predictions and are subject to, without limitation, (i) known and unknown risks, including the risks and uncertainties indicated from time to time in the final prospectus of Voyager relating to its initial public offering filed with the SEC, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by Voyager; (ii) uncertainties; (iii) assumptions; and (iv) other factors beyond Voyager’s or VERAXA’s control that are difficult to predict because they relate to events and depend on circumstances that will occur in the future. They are neither statements of historical fact nor promises or guarantees of future performance. Therefore, VERAXA’s actual results may differ materially and adversely from those expressed or implied in any forward-looking statements and Voyager and VERAXA therefore caution against relying on any of these forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Voyager and its management, VERAXA and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Voyager’s or VERAXA’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement and any subsequent definitive agreements with respect to the Business Combination; (ii) the outcome of any legal proceedings that may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (iii) the inability to complete the Business Combination due to the failure to obtain consents and approvals of the shareholders of Voyager, to obtain financing to complete the Business Combination or to satisfy other conditions to closing, or delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Business Combination Agreement; (iv) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (v) projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, and the estimated implied enterprise value of VERAXA; (vi) VERAXA’s ability to scale and grow its business, and the advantages and expected growth of VERAXA; (vii) VERAXA’s ability to source and retain talent, the cash position of VERAXA following closing of the Business Combination; (viii) the ability to meet stock exchange listing standards in connection with, and following, the consummation of the Business Combination; (ix) the risk that the Business Combination disrupts current plans and operations of VERAXA as a result of the announcement and consummation of the Business Combination; (x) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of VERAXA to grow and manage growth profitably, maintain key relationships and retain its management and key employees; (xi) costs related to the Business Combination; (xii) changes in applicable laws, regulations, political and economic developments; (xiii) the possibility that VERAXA may be adversely affected by other economic, business and/or competitive factors; (xiv) VERAXA’s estimates of expenses and profitability; (xv) the failure to realize estimated shareholder redemptions, purchase price and other adjustments; and (xvi) other risks and uncertainties set forth in the filings by Voyager with the SEC. There may be additional risks that neither Voyager nor VERAXA presently know or that Voyager and VERAXA currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Any forward-looking statements made by or on behalf of Voyager or VERAXA speak only as of the date they are made. None of Voyager or VERAXA undertakes any obligation to update any forward-looking statements to reflect any changes in their respective expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.
Additional Information and Where to Find It
In connection with the Business Combination Agreement, Voyager and/or VERAXA intend to file relevant materials with the SEC, including the Registration Statement, which will include a proxy statement/prospectus of Voyager, and will file other documents regarding the proposed transaction with the SEC. This communication is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Voyager has filed or may file with the SEC in connection with the proposed transaction. When available, the definitive proxy statement and other relevant materials for the proposed transaction will be mailed or made available to stockholders of Voyager as of a record date to be established for voting on the proposed transaction.
Before making any voting or investment decision, investors and stockholders of Voyager are urged to carefully read, when they become available, the entire registration statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, and the documents incorporated by reference therein, because they will contain important information about Voyager, VERAXA, and the proposed transaction. Voyager’s investors and stockholders and other interested persons will also be able to obtain copies of the registration statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, other documents filed with the SEC that will be incorporated by reference therein, and all other relevant documents filed with the SEC by Voyager in connection with the Transaction, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Voyager at the address set forth below.
Contact
| VERAXA Biotech AG | Voyager Acquisition Corp. |
| Dr. Christoph Antz CEO Telephone: +49-6221-3521330 Email: antz@veraxa.com | Mr. Adeel Rouf Chief Executive Officer, and Director Email: adeel@voyageracq.com |
| For Media & Investors Mario Brkulj Valency Communications Telephone: +49 160 9352 9951 Email: mbrkulj@valencycomms.eu | |
BiTAC is a trademark of VERAXA Biotech AG. | |
FAQ
What is the value of the VERAXA Biotech and Voyager Acquisition Corp (NASDAQ:VACH) merger?
How many shares will VERAXA shareholders receive in the Voyager (NASDAQ:VACH) merger?
When is the VERAXA and Voyager (NASDAQ:VACH) merger expected to close?
How much cash will be available from the Voyager SPAC trust?
Will existing VERAXA shareholders receive cash in the Voyager (NASDAQ:VACH) merger?
